Clinical Use of Combined First-Trimester Screening Test for Aneuploidy in A Low-Income Setting: Retrospective Study

低收入地区联合妊娠早期非整倍体筛查的临床应用:回顾性研究

阅读:2

Abstract

BACKGROUND: Although combined first trimester screening is effective at detecting fetal chromosomal anomalies which are trisomy 21, 18 and 13, there is scarce data on its practice and practice in low-income countries. This study presents data on clinical use of combined first trimester prenatal screening tests among pregnant women in a Sub-Saharan setting. METHODS: This retrospective study was conducted over 7 years between July 2016 and June 2023 at St. Paul's Hospital Millennium Medical College (Ethiopia). Risk assessment was done with Snibe 2000 software using maternal age, nuchal translucency, PAPP-A, β-hCG and other maternal characteristics. Statistical analysis was done using SPSS version 22. Fishers exact and Man Whitney U test were done as appropriate, and P-value less than 0.05 was used to present significance of the results. RESULTS: A total of 141 patients were included in the final analysis. Overall high-risk cases for aneuploidy based on the combined test was 24.8%. Screening positive for aneuploidy had an association with increased nuchal translucency [median (IQR) = 2.1 (1.7, 2.5) for screening negative vs 2.9 (2.4, 2.9) for screening positive test, p-value = 0.021] and low PAPP-A values ≤ 0.05 MoM (1 (5%) for negative and 5 (56%) for positive, p-value = 0.005). CONCLUSION: The prevalence of screening positive for high-risk aneuploidy in this study was higher than in previous reports which may be due to the fact that the study population is primary high-risk women. Nuchal translucency and low PAPP-A values were associated with screening positive for aneuploidy. Combined first trimester screening is feasible and effective for detecting fetal chromosomal anomalies in low-income settings. Laboratory capacity for performing serum analytes and genetic testing, and availability of nuchal translucency ultrasound services should acted up on for creating a wider access to such vital prenatal genetic screening and testing services.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。